[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cytokinetics (CYTK)

Cytokinetics (CYTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,469,351
  • Shares Outstanding, K 124,433
  • Annual Sales, $ 88,040 K
  • Annual Income, $ -784,960 K
  • EBIT $ -708 M
  • EBITDA $ -698 M
  • 60-Month Beta 0.38
  • Price/Sales 107.23
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 55.62% (+4.23%)
  • Historical Volatility 33.75%
  • IV Percentile 40%
  • IV Rank 10.07%
  • IV High 183.58% on 05/04/26
  • IV Low 41.30% on 06/12/26
  • Expected Move (DTE 1) 3.11 (4.00%)
  • Put/Call Vol Ratio 0.48
  • Today's Volume 444
  • Volume Avg (30-Day) 841
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 83,000
  • Open Int (30-Day) 79,435
  • Expected Range 74.63 to 80.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.52
  • Number of Estimates 8
  • High Estimate $-1.39
  • Low Estimate $-1.65
  • Prior Year $-1.54
  • Growth Rate Est. (year over year) +1.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
72.12 +7.79%
on 08/14/26
83.83 -7.26%
on 07/22/26
-2.44 (-3.04%)
since 07/17/26
3-Month
66.63 +16.67%
on 06/10/26
88.31 -11.97%
on 06/30/26
+1.29 (+1.69%)
since 05/19/26
52-Week
35.22 +120.73%
on 08/29/25
88.31 -11.97%
on 06/30/26
+39.90 (+105.44%)
since 08/19/25

Most Recent Stories

More News
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 14, 2026 it granted stock options to purchase an aggregate of 27,565...

CYTK : 77.74 (+2.16%)
Cytokinetics: Q2 Earnings Snapshot

Cytokinetics: Q2 Earnings Snapshot

CYTK : 77.74 (+2.16%)
Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update

MYQORZO ® (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive...

CYTK : 77.74 (+2.16%)
Cytokinetics: Tomorrow's Loss Estimate Has Already Been Perfectly Calibrated to Disappoint No One

Barchart Research What to Expect from CYTK Earnings CYTK Generated August 5, 2026 Current Price $78.85 EPS Estimate $$-1.63 Consensus Rating Strong Buy Average Move 5.02% Cytokinetics: Tomorrow's Loss...

CYTK : 77.74 (+2.16%)
Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales

Authorisation from MRHA and Recommendation from NICE This announcement is intended for business and financial media and investors only  SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE)...

CYTK : 77.74 (+2.16%)
Cytokinetics to Announce Second Quarter Results on August 6, 2026

SOUTH SAN FRANCISCO, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 6, 2026 at 4:00...

CYTK : 77.74 (+2.16%)
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 15, 2026 it granted stock options to purchase an aggregate of 21,220...

CYTK : 77.74 (+2.16%)
Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy Company to Host In-Person and Virtual...

CYTK : 77.74 (+2.16%)
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2026 it granted stock options to purchase an aggregate of 24,784...

CYTK : 77.74 (+2.16%)
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program

Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is August 3, 2026 SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE)...

CYTK : 77.74 (+2.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology...

See More

Key Turning Points

3rd Resistance Point 80.07
2nd Resistance Point 78.97
1st Resistance Point 78.36
Last Price 77.74
1st Support Level 76.65
2nd Support Level 75.55
3rd Support Level 74.94

See More

52-Week High 88.31
Last Price 77.74
Fibonacci 61.8% 68.03
Fibonacci 50% 61.76
Fibonacci 38.2% 55.50
52-Week Low 35.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.